98 results about "Tissue fibrosis" patented technology

The invention belongs to the technical field of biological medicines, and particularly relates to application of oxibenzophenone in preparation of a medicine for treating pathological cardiac hypertrophy and / or heart failure. Research results in myocardial cells of primary newborn rats show that Exibenzophenone can inhibit pathological hypertrophy of myocardial cells induced by phenylephrine (PE). Animal experiments show that the epoxybenzophenone can improve cardiac dysfunction induced by aortic arch constriction (TAC) and reduce cardiac hypertrophy and cardiac tissue fibrosis. The invention provides a new drug research and development approach and a drug action target for treating pathological cardiac hypertrophy and heart failure, and has very important medicinal value.

Provided are a recombinant human interleukin-11 mutant, and a conjugate of the mutant conjugated to a chemical molecule and a use thereof. The recombinant human interleukin-11 mutant achieves soluble expression in an Escherichia coli expression system by means of an SUMO sequence tandem fusion method. The conjugate is obtained by the site-specific conjugation of the mutant to the chemical molecule at a mutant amino acid residue in position W147 by means of a covalent bond. The chemical molecule is at least one of polyethylene glycol, an alkanoic acid aliphatic chain, and a hydrophilic high-molecular polymer containing an alkanoic acid aliphatic chain. The conjugate retains the binding capacity to human interleukin-11 receptor A while demonstrating significantly reduced binding capacity to human IL-6 signal transducer receptor. The conjugate shows the ability to block the signaling between human IL-11 and IL-11 RA and between human IL-11 and GP130 either in vivo or in vitro and can be used for the treatment of associated diseases with tissue fibrosis as a clinical manifestation caused by elevated primary or secondary IL-11.

The invention relates to a CD44 receptor and scavenger receptor-A (SR-A) dual-targeting pharmaceutical composition as well as a preparation method and application thereof. According to the invention, a certain proportion of carrier material with CD44 receptor targeting capability is adsorbed on the fatty acid albumin nanoparticles, and the albumin nanoparticles with CD44 receptor and SR-A dual-targeting capability are successfully prepared. The albumin nanoparticles can simultaneously deliver drugs to activated macrophages with high SR-A specificity expression and fibroblasts or tumor cells with high CD44 receptor specificity expression, provide new treatment schemes and ideas for various diseases including tissue fibrosis and tumors, and have great application value in the field of biological medicine.

Disclosed examples include technology for the detection and treatment of neotissue formation proximate an implantable stimulator. Neotissue formation can include ossification, scar tissue, soft tissue fibrosis, and other tissue growth. The neotissue formation can be detected by analyzing (e.g., using a machine-learning framework) stimulation data relating to the implantable stimulator. Neotissue formation characteristics can be analyzed to determine appropriate treatment actions for ameliorating the effects of neotissue formation.

Provided herein are methods of treating or preventing the formation of orthopedic-related fibrosis, which included but not limited to peri-implant fibrotic tissue, bone-to-bone fibrosis, bone-to-soft tissue fibrosis, soft tissue-to-soft tissue fibrosis, joint related fibrosis, in a subject in a subject in need thereof. In certain embodiments, the method includes administering to the subject an inhibitor of ADGRF5, GREM1, PTPRF, LAMB1, EFEMP1, DNMT3b, RSPO3, ACTA2, PDGFRA, PDGFB, PDGFA, CX3CR1, TBX18, PERI, NR1D1, RYR1, DES, KLF4, KLHL41, DUSP1, or TNNT3 to the subject.

The invention discloses a biological medicine application of luwulinine, and provides and verifies that luwulinine can inhibit disulfiram death of cells for the first time, so that luwulinine can be used for preventing or treating hepatic ischemia reperfusion injury. Experimental data show that the luteiniine can relieve liver function injury after reperfusion with cell apoptosis, tissue inflammation infiltration and tissue fibrosis as manifestations, and a new direction is provided for mechanism research and prevention and treatment of hepatic ischemia reperfusion injury.

The invention relates to application of a UHRF1 inhibitor in preparation of a medicine for treating tissue fibrosis after spinal cord injury, and belongs to the technical field of biological medicine. The invention proves that the expression of UHRF1 can be increased due to spinal cord injury; compared with mice of a false operation group, the mice of which the UHRF1 is specifically knocked down in the fibroblasts have the advantages that fibrosis caused by spinal cord injury is obviously reduced, nerve regeneration is promoted, and the motor function is obviously improved. In the aspect of mechanism, the knock-down of UHRF1 leads to the reduction of the number of proteins combined on a PPM1A gene promoter, the weakening of the transcription inhibition effect and the promotion of the expression of the PPM1A gene, while the PPM1A can inhibit the phosphorylation of Smad2 / 3 and inhibit the conduction of a TGF-beta1 / Smads pathway, thereby inhibiting tissue fibrosis.

This invention relates to the field of traditional Chinese medicine and natural medicines, and discloses a traditional Chinese medicine composition for treating thyroiditis, nodular goiter, and thyroid nodules, as well as its preparation method and application. The traditional Chinese medicine composition is made from raw materials in parts by weight of 1-30 parts of Prunella vulgaris, 1-30 parts of Taraxacum mongolicum, 1-30 parts of Hordeum vulgare malt, 1-20 parts of Citrus reticulata peel, 1-24 parts of Crataegus pinnatifida, and 1-24 parts of Raphanus sativus seed. It can not only significantly reduce serum TgAb and TPOAb antibody levels, inhibiting the attack of autoimmune response on the thyroid gland from the source, but also effectively reduce lymphocyte infiltration, repair damaged thyroid follicular structure and restore colloid content, thereby reversing immune damage and tissue destruction of the thyroid gland, reducing thyroid nodules, and solving the problems of existing treatments for thyroiditis, nodular goiter, and thyroid nodules that cannot reverse immune damage to the thyroid gland, destruction of follicular structure, and tissue fibrosis.

The present invention discloses the use of CTRP13 in the preparation of a drug for treating renal fibrosis. Experimental studies have shown that CTRP13 inhibits Smad3, inhibiting renal tubular epithelial cell transdifferentiation, thereby preventing and / or treating renal fibrosis. Furthermore, CTRP13 lacks the common hepatotoxicity and renal cytotoxicity seen with other renal fibrosis inhibitors, thus demonstrating its safety. This suggests that CTRP13 could be widely used as a drug for treating renal fibrosis caused by infections, drugs, aging, hypertension, and other conditions.

The invention belongs to the technical field of biological medicines, and particularly relates to application of MIM2 and derivatives thereof in preparation of products for treating tissue fibrosis. It is found that the compound MIM2 can effectively inhibit expression and synthesis of various cancers (extracellular matrix proteins such as collagen and laminin in cells). In-vitro experiments show that after MIM2 treatment, collagen and laminin expression of the cancer cells, skin fibroblasts, hepatic stellate cells and embryonic lung cells is remarkably reduced. Animal experiments further prove that the MIM2 can effectively inhibit collagen deposition in tumor tissues of tumor-bearing mice, can slow down the fibrosis process of liver fibrosis and pulmonary fibrosis mouse models, and can reduce the level of plasma hyaluronic acid at the same time. The results show that the MIM2 has the effects of inhibiting extracellular matrix deposition and delaying tissue fibrosis, and is expected to be developed into small molecular drugs for treating cancer-related fibrosis and other fibrosis diseases.

The integrin family of cell adhesion molecules has emerged as key mediators of tissue fibrosis. A pharmacological inhibitor of multiple integrin subtypes is required to produce meaningful effects on delaying or inhibiting the progression of fibrosis. Monoclonal antibodies recognizing multiple integrins with potent neutralizing activity and having human and mouse cross-reactivity are described. In particular, monoclonal antibodies that bind human αvβ1, αvβ3, αvβ5, αvβ36, αvβ38, and α5β1 integrins and mouse αvβ1, αvβ3, αvβ5, αvβ6, and αvβ8 integrins are described.

The application discloses application of a novel peptide UHP in preparation of a medicine for treating and / or preventing delayed aging, and belongs to the technical field of biological medicines.The novel peptide UHP is composed of 37 L-type amino acids including a transmembrane peptide HIV-TAT.It is proved by cell experiments that the novel peptide UHP significantly improves the aging phenotype of a HGPS cell model simulated by overexpression of progerin and a replicative senescent human normal fibroblast cell, reduces the SA-beta-gal positive cell proportion and the expression of SASP factors, and increases the expression levels of cell proliferation markers Ki67, Lamin B1 and Cyclin A2.It is proved by animal experiments that the novel peptide UHP can improve the progeria phenotype, body weight and exercise capacity of a progeria mouse, relieve fibrosis in multiple tissues, improve the skin aging phenotype, and prolong the survival period of the progeria mouse, thereby providing a new medicine selection for clinical treatment of aging-related diseases.

To provide a novel TGF-β signal transduction inhibitor.SOLUTION: An extract of Oenothera biennis L. is used as an active ingredient. The extract of Oenothera biennis L. has a TGF-β signal transduction inhibitory effect and thus suppresses TGF-β-induced promotion of fibrosis in tissues. Therefore, it can be expected to have preventive and therapeutic effects on fibrotic diseases, and preventive and improving effects on cellulite.SELECTED DRAWING: Figure 1

The invention belongs to the technical field of biomedicine, and particularly discloses an endowed mesenchymal stem cell, an endowed mesenchymal stem cell composition and application of the endowed mesenchymal stem cell composition to preparation of a medicine for treating organ insufficiency, and the endowed mesenchymal stem cell is obtained by treating human mesenchymal stem cells with ingenol HEP14. The energizing mesenchymal stem cell composition comprises energizing mesenchymal stem cells and HEP14 / PLGA microspheres which are prepared by adopting a polylactic acid-glycolic acid copolymer (PLGA) as a carrier and have high HEP14 loading capacity and long-acting HEP14 slow release. The energized mesenchymal stem cell has the effects of enhancing the survival activity and dryness of the mesenchymal stem cell, resisting tissue fibrosis, promoting tissue angiogenesis, and promoting tissue regeneration and functional recovery; the endowed mesenchymal stem cells and the HEP14 / PLGA microspheres are used in a combined manner, and the retention and transdifferentiation effects of the endowed mesenchymal stem cells in tissues are enhanced, so that the functions of the endowed mesenchymal stem cells and the application of the endowed mesenchymal stem cells in the field of regenerative medicine are further enhanced.

A treatment composition for inhibiting systemic sclerosis Vimentin mutant protein activity by using an STAT6 inhibitor, which inhibits the expression of an M2 macrophage and a profibrotic T cell which are immunocytes related to systemic sclerosis, and increases the expression of a Treg, and inhibits the expression of TGF-β, Col1a1, and α-SMA which are fibrosis factors related to systemic sclerosis. The presence of a pSTAT6 expression CD8 T cell in a fibrosis tissue has been identified, and that the expression of a pSTAT6 expression CD8 T positive cell is controlled via injection of the STAT6 inhibitor. In an animal model with increased Vimentin-specific disease symptom activity, the STAT6 inhibitor inhibits antigen-specific tissue fibrosis of systemic sclerosis with activated disease symptoms, and that the STAT6 inhibitor inhibits the expression of IL-17 cytokine expression CD8 positive TRM capable of inducing fibrosis and cell inflammation which are systemic sclerosis diseases.

The present application provides a biological active peptide from seawater pearl, the sequence of which is Ile-Pro-Ser-Thr-Thr-Pro-Phe-Pro-Ser-Thr-Thr-Val-Ala-Thr-Thr-Thr-Met, and the name of which is SCOL polypeptide. The biological active peptide can improve an ACE2 enzyme activity to 3.76 times, and can be applied in preparation of a drug improving an ACE2 activity, treating hypertension, anti-heart failure, anti-tissue fibrosis, anti-inflammation, and type 2 diabetes mellitus and the complication thereof, and relieving neuropathic pain. The biological active peptide can be specifically bound to the ACE2, effectively inhibits the 65% binding between novel coronavirus S protein and the ACE2, can be applied in preparation of an anti-coronavirus infection drug as an inhibitor, and specifically applied in preparation of anti-novel coronavirus drug.

The invention provides application of plant hormone mitochondrial acid 5 in preparation of a medicine for treating myocardial injury caused by diabetes, and relates to the technical field of biological medicine. In the aspects of blood sugar and blood fat, the MA-5 reduces the blood sugar and blood fat levels of the mouse with the type 2 diabetes mellitus; in the aspect of cardiac injury involved by diabetes, MA-5 inhibits cardiac tissue fibrosis, improves mitochondrial injury, inhibits oxidative stress and reduces ROS (reactive oxygen species) generation. The MA-5 has the effects of stably reducing blood glucose and protecting diabetic cardiomyopathy. The composition is simple and clear; the taking is convenient; the price is low, and the like. Compared with the existing medicines for treating diabetes and diabetic cardiomyopathy, the chemical components of the MA-5 are simple and clear, the action mechanism of the MA-5 is easier to clarify in pharmacological research, and the quality of the medicines is easier to control in production. According to the application, a powerful experimental basis and a theoretical basis are provided for preventing and treating the type 2 diabetes mellitus and myocardial complications of the type 2 diabetes mellitus by the MA-5.

The present invention includes a method of treating fibrosis in a human patient in need thereof comprising administering to the human patient in need of treatment a therapeutically effective amount of Prolactin-Inducible Protein (PIP) which is capable of inhibiting or reversing the formation of pathogenic fibrils, e g., fibrosis that affects at least one organ selected from the group consisting of skin, intestine, heart, liver, lung, and kidney.

This invention relates to a formulation and method of application of a multicomponent mycotoxin detoxifier for poultry feed, particularly female broiler chickens, which aims to provide protection to the Bursa Fabricius due to exposure to mycotoxins in the form of aflatoxin and ochratoxin. The mycotoxin detoxifier formulation according to this invention consists of an inorganic mycotoxin binder in the form of bentonite and / or zeolite, an organic mycotoxin binder in the form of pectin and / or esterified cellulose, and a natural antioxidant in the form of vitamin E and / or antioxidant herbal extracts. The formulation is applied to poultry feed at a dose of 2 to 2.5 g per kg of feed and is able to bind aflatoxin and ochratoxin simultaneously in the digestive tract, thereby reducing the bioavailability of mycotoxins.The application of this formulation has been proven to reduce histopathological damage to the Bursa of Fabricius, including lymphoid follicle depletion, cyst formation, cell necrosis, inflammatory cell infiltration, and tissue fibrosis, while also supporting the immune system function of female broiler chickens. This invention provides an effective, efficient, and easily applicable technical solution in the poultry farming industry to address mixed mycotoxin contamination in feed.

The invention relates to an application of a succinate dehydrogenase subunit SDHC protein and a coding gene thereof in preparation of a medicine for preventing and / or treating renal fibrosis, and belongs to the field of biological medicines. The invention proposes and verifies that SDHC gene delivery can alleviate kidney pathological changes of chronic kidney diseases for the first time; the expression level of kidney tissue fibrosis related indexes is reduced; the transdifferentiation of renal tubular epithelial cells to myofibroblasts is inhibited. SDHC gene delivery can achieve the effect of improving the chronic kidney disease, and good development and application prospects are achieved.

The present disclosure provides a composition for treating or preventing fibrosis and / or inflammation in an organ or tissue in a subject. The present disclosure specifically provides a composition for treating or preventing fibrosis and / or inflammation in an organ or tissue in a subject, the composition containing macrophages derived from monocytes stimulated with IL-34. The composition can be produced by a method comprising: a step for preparing a sample comprising CD14-positive cells; an optional step for isolating the CD14-positive cells from the sample if required; and a step for bringing the sample or the isolated CD14-positive cells into contact with IL-34.

Hydrophilic modification is carried out on halofuginone through carboxyl polyethylene glycol with a benzocyclooctyne group to obtain benzocyclooctyne-polyethylene glycol-halofuginone (CPH) with good biocompatibility, and the CPH is used for anti-tissue fibrosis treatment through glycometabolism engineering and orthogonal click chemistry. Compared with halofuginone small molecules, the CPH has negligible cytotoxicity. The combination of CPH and glycometabolism engineering has a good treatment effect on tissue fibrosis.

This disclosure generally relates to the use of (24S)-3β-hydroxy-5α-stigmastan-6-one in the preparation of a medicament for the treatment of benign prostatic hyperplasia, inflammation or fibrosis, and the medicament being administered to individuals in need of treatment at a dose of 0.1-50 mg / kg body weight.

The invention belongs to the field of biological medicine, and particularly relates to application of a compound YS434 in preparation of medicine for preventing and / or treating pulmonary fibrosis and a medicine composition of the compound YS434. The small molecule compound YS434 can treat pulmonary fibrosis by reducing collagenous fiber deposition, relieving inflammatory response, promoting alveolar epithelial tissue repair and inhibiting the pulmonary tissue fibrosis process, provides a new choice for the medicine for clinically treating pulmonary fibrosis, and has a good application prospect.

The invention relates to the technical field of biological medicines, in particular to application of wild buckwheat rhizome freeze-dried powder in preparation of a medicine for preventing or treating antimony pneumoconiosis. A mouse antimony pneumoconiosis model is constructed by injecting an antimony (Sb) suspension into a trachea, and pulmonary fibrosis lesion caused by antimony exposure can be remarkably relieved by intragastric administration of the wild buckwheat rhizome freeze-dried powder prepared by the invention. Experimental results show that Hamp; e dyeing indicates that the freeze-dried powder can obviously relieve the fibrosis severity of the lung tissue; western Blot and PCR (Polymerase Chain Reaction) detection results show that the wild buckwheat rhizome can partially inhibit the expression up-regulation of Col-1 and alpha-SMA induced by antimony in protein and gene levels; in addition, the wild buckwheat rhizome can also obviously reduce the content of hydroxyproline in lung tissues. The results show that the wild buckwheat rhizome freeze-dried powder can effectively improve multiple pathological indexes and reduce the pulmonary fibrosis degree, has good potential in the aspect of preventing antimony pneumoconiosis, and has potential application value.

The invention relates to the technical field of immunotherapy, in particular to a method for preparing CAR-M and / or CAR-T with enhanced cell killing ability. The method comprises the steps that CAR-M and / or CAR-T are / is cultured on hydrogel, so that the CAR-M and / or CAR-T with the enhanced cell killing capacity are / is obtained, the hydrogel is gelatin-oxidized sodium alginate cross-linked hydrogel, and the oxidation degree is 50%; the material has the energy storage modulus of 1953 to 1120Pa, the loss modulus of 112.0 to 42.81 Pa, the loss coefficient of 0.06945 to 0.03730 and the stress relaxation coefficient of 2915 to 2019s. The CAR-M cell therapy is introduced into pulmonary fibrosis treatment for the first time, and hydrogel with optimal parameters is combined, so that the treatment efficiency of CAR-M / CAR-T cells is improved, the killing ability is improved by at least four times, and pulmonary tissue fibrosis is effectively relieved.

Polypeptides having the amino acid of one of SEQ ID NO: 1-9 are provided that bind to convex protein target sites on transformimg growth factor beta receptor type 2 (TGFbRII), cytotoxic T-lymphocyte associated protein 4 (CTLA-4), or programmed death-ligand 1 (PD-L1), and methods for their use in treating cancer or tissue fibrosis.

The present application provides methods for treating or preventing diseases and conditions associated with tissue fibrosis.

The invention belongs to the field of animal models, and particularly relates to a construction method and application of a humanized COL3A1 gene mouse model. Based on a gene editing means, fixed-point insertion is performed on the human COL3A1 gene, a fertilized ovum with the mutation can develop an adult COL3A1 gene mouse model, and a foundation is laid for researching the structure and the biological effect of III-type collagen. And a favorable model is provided for evaluating related diseases such as skin, heart and tissue fibrosis and related medicines, cosmetics and medical instruments of the diseases.

The application provides a traditional Chinese medicine external application method for reducing the risk of fistula fibrosis in dialysis patients, relates to the technical field of clinical application of traditional Chinese medicine, is suitable for the prevention of autologous arteriovenous fistula fibrosis of maintenance hemodialysis patients, can effectively reduce the incidence of complications such as fistula peripheral tissue fibrosis and vascular stenosis, and prolongs the service life of the fistula. The drug stability and skin permeability are improved through optimization of adjuvants, and based on the grouping intervention of maintenance hemodialysis patients, the fistula blood flow and fibrosis improvement are evaluated in combination with color Doppler ultrasound. The application takes the principles of promoting blood circulation to remove blood stasis, dredging collaterals and resolving knots, and detoxification and swelling reduction as the therapeutic principles, prepares a fistula protection ointment by screening and optimizing a traditional Chinese medicine formula, realizes the effects of improving local microcirculation of the fistula, inhibiting fibrous tissue proliferation and reducing inflammatory reactions through external application intervention, thereby reducing the incidence of fistula fibrosis and related complications, prolonging the fistula patency time, simultaneously reducing the treatment cost, and improving the patient tolerance and life quality.